Pacific Edge Past Earnings Performance
Past criteria checks 0/6
Pacific Edge's earnings have been declining at an average annual rate of -9.9%, while the Biotechs industry saw earnings growing at 13% annually. Revenues have been growing at an average rate of 37.2% per year.
Key information
-9.9%
Earnings growth rate
3.3%
EPS growth rate
| Biotechs Industry Growth | 14.8% |
| Revenue growth rate | 37.2% |
| Return on equity | -46.3% |
| Net Margin | -124.0% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
Recent updates
Here's Why We're Watching Pacific Edge's (NZSE:PEB) Cash Burn Situation
Feb 19
Lacklustre Performance Is Driving Pacific Edge Limited's (NZSE:PEB) 30% Price Drop
Dec 18Fewer Investors Than Expected Jumping On Pacific Edge Limited (NZSE:PEB)
Jun 06Pacific Edge Limited (NZSE:PEB) Annual Results: Here's What Analysts Are Forecasting For This Year
May 27We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely
May 23Companies Like Pacific Edge (NZSE:PEB) Are In A Position To Invest In Growth
Sep 06Pacific Edge (NZSE:PEB) Is In A Good Position To Deliver On Growth Plans
May 31Pacific Edge (NZSE:PEB) Is In A Strong Position To Grow Its Business
Jan 17We're Hopeful That Pacific Edge (NZSE:PEB) Will Use Its Cash Wisely
Jun 05Pacific Edge Limited (NZSE:PEB): Are Analysts Optimistic?
May 14Don't Ignore The Fact That This Insider Just Sold Some Shares In Pacific Edge Limited (NZSE:PEB)
Mar 21Did The Underlying Business Drive Pacific Edge's (NZSE:PEB) Lovely 750% Share Price Gain?
Mar 13Have Insiders Been Selling Pacific Edge Limited (NZSE:PEB) Shares?
Feb 14
Pacific Edge Limited's (NZSE:PEB) Profit Outlook
Jan 18How Much Of Pacific Edge Limited (NZSE:PEB) Do Insiders Own?
Dec 23Did You Participate In Any Of Pacific Edge's (NZSE:PEB) Incredible 434% Return?
Nov 21Revenue & Expenses BreakdownBeta
How Pacific Edge makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 26 | -32 | 39 | 10 |
| 30 Jun 23 | 23 | -29 | 37 | 9 |
| 31 Mar 23 | 21 | -27 | 35 | 8 |
| 31 Dec 22 | 19 | -24 | 32 | 7 |
| 30 Sep 22 | 16 | -21 | 28 | 6 |
| 30 Jun 22 | 15 | -21 | 25 | 6 |
| 31 Mar 22 | 13 | -20 | 22 | 5 |
| 31 Dec 21 | 12 | -18 | 20 | 5 |
| 30 Sep 21 | 12 | -16 | 18 | 5 |
| 30 Jun 21 | 10 | -15 | 17 | 5 |
| 31 Mar 21 | 9 | -14 | 15 | 5 |
| 31 Dec 20 | 7 | -15 | 14 | 4 |
| 30 Sep 20 | 6 | -17 | 14 | 4 |
| 30 Jun 20 | 5 | -18 | 14 | 4 |
| 31 Mar 20 | 5 | -19 | 15 | 4 |
| 31 Dec 19 | 5 | -19 | 15 | 5 |
| 30 Sep 19 | 5 | -19 | 15 | 6 |
| 30 Jun 19 | 5 | -18 | 15 | 5 |
| 31 Mar 19 | 5 | -18 | 15 | 4 |
| 31 Dec 18 | 5 | -18 | 15 | 2 |
| 30 Sep 18 | 5 | -18 | 15 | 0 |
| 30 Jun 18 | 5 | -19 | 15 | 0 |
| 31 Mar 18 | 5 | -20 | 16 | 0 |
| 31 Dec 17 | 4 | -20 | 18 | 0 |
| 30 Sep 17 | 3 | -21 | 20 | 0 |
| 30 Jun 17 | 4 | -22 | 17 | 0 |
| 31 Mar 17 | 4 | -23 | 14 | 0 |
| 31 Dec 16 | 6 | -21 | 9 | 0 |
| 30 Sep 16 | 8 | -20 | 4 | 0 |
| 30 Jun 16 | 7 | -18 | 4 | 0 |
| 31 Mar 16 | 6 | -16 | 3 | 0 |
| 31 Dec 15 | 5 | -15 | 3 | 0 |
| 30 Sep 15 | 4 | -15 | 3 | 0 |
| 30 Jun 15 | 4 | -14 | 3 | 0 |
| 31 Mar 15 | 3 | -12 | 3 | 0 |
| 31 Dec 14 | 3 | -11 | 4 | 0 |
| 30 Sep 14 | 2 | -10 | 5 | 0 |
| 30 Jun 14 | 1 | -10 | 5 | 0 |
| 31 Mar 14 | 1 | -10 | 5 | 0 |
| 31 Dec 13 | 0 | -9 | 3 | 0 |
| 30 Sep 13 | 0 | -9 | 1 | 0 |
| 30 Jun 13 | 0 | -8 | 1 | 0 |
Quality Earnings: PEB is currently unprofitable.
Growing Profit Margin: PEB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PEB is unprofitable, and losses have increased over the past 5 years at a rate of 9.9% per year.
Accelerating Growth: Unable to compare PEB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PEB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.6%).
Return on Equity
High ROE: PEB has a negative Return on Equity (-46.33%), as it is currently unprofitable.